KR100949539B1 - 약학 조성물용 입자의 제조 방법 - Google Patents

약학 조성물용 입자의 제조 방법 Download PDF

Info

Publication number
KR100949539B1
KR100949539B1 KR1020027017595A KR20027017595A KR100949539B1 KR 100949539 B1 KR100949539 B1 KR 100949539B1 KR 1020027017595 A KR1020027017595 A KR 1020027017595A KR 20027017595 A KR20027017595 A KR 20027017595A KR 100949539 B1 KR100949539 B1 KR 100949539B1
Authority
KR
South Korea
Prior art keywords
particles
excipient
pharmaceutical composition
additive
milling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027017595A
Other languages
English (en)
Korean (ko)
Other versions
KR20030051439A (ko
Inventor
모톤데이빗알렉산더보든
스태니포스죤니콜라스
무사로젤라
Original Assignee
벡투라 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100949539(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0029263A external-priority patent/GB0029263D0/en
Priority claimed from PCT/GB2001/001732 external-priority patent/WO2001078694A2/en
Application filed by 벡투라 리미티드 filed Critical 벡투라 리미티드
Publication of KR20030051439A publication Critical patent/KR20030051439A/ko
Application granted granted Critical
Publication of KR100949539B1 publication Critical patent/KR100949539B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020027017595A 2000-06-27 2001-06-27 약학 조성물용 입자의 제조 방법 Expired - Lifetime KR100949539B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP00113608.4 2000-06-27
EP00113608 2000-06-27
GB0029263.1 2000-11-30
GB0029263A GB0029263D0 (en) 2000-11-30 2000-11-30 Method of making particles for use in a pharmaceutical composition
PCT/GB2001/001732 WO2001078694A2 (en) 2000-04-17 2001-04-17 Formulations for use in inhaler devices
GBPCT/GB01/01732 2001-04-17

Publications (2)

Publication Number Publication Date
KR20030051439A KR20030051439A (ko) 2003-06-25
KR100949539B1 true KR100949539B1 (ko) 2010-03-25

Family

ID=26071085

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017595A Expired - Lifetime KR100949539B1 (ko) 2000-06-27 2001-06-27 약학 조성물용 입자의 제조 방법

Country Status (13)

Country Link
US (4) US7744855B2 (https=)
EP (3) EP1296651B2 (https=)
JP (1) JP5698423B2 (https=)
KR (1) KR100949539B1 (https=)
CN (1) CN100551358C (https=)
AT (1) ATE378039T1 (https=)
CA (1) CA2413692C (https=)
DE (1) DE60131399T3 (https=)
DK (1) DK1913939T3 (https=)
ES (2) ES2292598T3 (https=)
IL (2) IL153705A0 (https=)
PT (2) PT1913939T (https=)
WO (1) WO2002000197A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078162A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
KR20210044336A (ko) 2019-10-14 2021-04-23 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
WO2024136219A1 (ko) * 2022-12-19 2024-06-27 주식회사 포스테라헬스사이언스 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
JP5698423B2 (ja) 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
ES2474199T3 (es) * 2000-11-30 2014-07-08 Vectura Limited Composiciones farmacéuticas para inhalaci�n
DE60140268D1 (de) 2000-11-30 2009-12-03 Vectura Ltd Partikel zur verwendung in einer pharmazeutischen zusammensetzung
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
CN102688224A (zh) * 2003-04-14 2012-09-26 维克特拉有限公司 用于提高剂量效率的药物组合物和装置
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
ATE301990T1 (de) 2003-07-25 2005-09-15 Ferring Bv Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
JP2007505831A (ja) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド 肺吸入による、早漏を治療するための医薬品組成物
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
MX2007009656A (es) 2005-02-10 2007-11-07 Glaxo Group Ltd Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma.
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
CA2699172C (en) * 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2296628B1 (en) 2008-05-22 2014-05-14 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
US9956170B2 (en) 2008-06-26 2018-05-01 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2309984B1 (en) 2008-07-02 2018-04-11 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
EP2370070B9 (en) 2008-11-25 2014-04-23 Boehringer Ingelheim Vetmedica GmbH Pimobendan for use in the treatment of hypertrophic cardiomyopathy in cats.
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
JP2012524815A (ja) * 2009-04-24 2012-10-18 シェーリング コーポレイション 乾燥粉末吸引器において有用な凝集体配合物
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
SG181673A1 (en) * 2009-12-14 2012-07-30 Chiesi Farma Spa Antibiotic microparticles for inhalation
PT2560611T (pt) * 2010-04-21 2018-02-07 Chiesi Farm Spa Processo para proporcionar partículas com cargas eletrostáticas reduzidas
US9228785B2 (en) 2010-05-04 2016-01-05 Alexander Poltorak Fractal heat transfer device
JP2013529606A (ja) 2010-06-22 2013-07-22 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 抗ムスカリン薬含有乾燥粉末配合物
PE20130601A1 (es) 2010-08-03 2013-05-30 Chiesi Farma Spa Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
TW201306847A (zh) 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
CN104470503A (zh) * 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
RS57799B1 (sr) * 2013-07-11 2018-12-31 Chiesi Farm Spa Formulacija suvog praha za administriranje inhalacijom, koja obuhvata atniholinergik, kortikosteroid i beta-adrenergik
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
ES2883448T3 (es) 2013-12-04 2021-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
CN112656780A (zh) 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 用于吸入的干粉制剂
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
EP4218734A1 (en) * 2014-07-31 2023-08-02 Vectura Inc. Dry powder formulations for inhalation
JP6684275B2 (ja) * 2014-10-08 2020-04-22 ザンボン ソシエタ ペル アチオニ ブデソニド及びホルモテロールを含有する医薬組成物
WO2016055544A1 (en) * 2014-10-08 2016-04-14 Eratech S.R.L. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
MX392636B (es) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
MA40910A (fr) * 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
US10830545B2 (en) 2016-07-12 2020-11-10 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a heat sink
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
JPWO2019009335A1 (ja) * 2017-07-04 2020-07-02 村上　正裕 微粒子の製造方法及び微粒子
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3866773B1 (en) 2018-10-16 2024-08-28 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
US12269041B2 (en) 2019-09-19 2025-04-08 New Jersey Institute Of Technology Spherical composite powder
WO2021127452A1 (en) 2019-12-19 2021-06-24 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
CN119278026A (zh) 2022-03-31 2025-01-07 好利安科技有限公司 吸入复合材料和基于载体的制剂组合
US20240261224A1 (en) 2022-12-02 2024-08-08 Kinaset Therapeutics, Inc. Formulation of a pan-jak inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023485A1 (en) * 1994-02-28 1995-08-31 Voxson International Pty. Limited Multi-mode communications system

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
US4349542A (en) 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
DE3917617A1 (de) 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
KR100208979B1 (ko) * 1992-06-12 1999-07-15 야스이 쇼사꾸 기도내 투여용 제제
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
DK0824344T3 (da) 1995-05-09 2005-08-15 Phoqus Pharmaceuticals Ltd Pulverformig sammensætning til elektrostatisk coating af farmaceutiske substrater
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9526495D0 (en) 1995-12-23 1996-02-28 Knoll Ag Therapeutic agents
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5955023A (en) * 1996-11-27 1999-09-21 Callutech, Llc Method of forming composite particle products
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
OA11529A (en) * 1998-03-16 2004-05-07 Inhale Therapeutic Syst Aerosolized active agent delivery.
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
AU772798B2 (en) 1999-04-21 2004-05-06 1355540 Ontario Inc. Formulations for detecting asthma
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
JP5698423B2 (ja) * 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
DE60140268D1 (de) 2000-11-30 2009-12-03 Vectura Ltd Partikel zur verwendung in einer pharmazeutischen zusammensetzung
ES2474199T3 (es) 2000-11-30 2014-07-08 Vectura Limited Composiciones farmacéuticas para inhalaci�n
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US20060147389A1 (en) 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US9192915B2 (en) * 2008-05-10 2015-11-24 Brigham Young University Porous composite particulate materials, methods of making and using same, and related apparatuses
WO2011092130A1 (de) * 2010-01-27 2011-08-04 Basf Se Beschichtungsmittel enthaltend kompositpartikel
US8491908B2 (en) * 2010-06-01 2013-07-23 Canon Kabushiki Kaisha Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023485A1 (en) * 1994-02-28 1995-08-31 Voxson International Pty. Limited Multi-mode communications system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int'l J. Pharm., 172, pp179-188.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078162A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
KR20210044336A (ko) 2019-10-14 2021-04-23 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
WO2024136219A1 (ko) * 2022-12-19 2024-06-27 주식회사 포스테라헬스사이언스 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법

Also Published As

Publication number Publication date
US10561613B2 (en) 2020-02-18
DK1913939T3 (en) 2017-09-18
IL153705A0 (en) 2003-07-06
EP2266549A2 (en) 2010-12-29
HK1056115A1 (en) 2004-02-06
ATE378039T1 (de) 2007-11-15
KR20030051439A (ko) 2003-06-25
DE60131399D1 (de) 2007-12-27
JP5698423B2 (ja) 2015-04-08
EP1296651B1 (en) 2007-11-14
PT1913939T (pt) 2017-07-19
US9351928B2 (en) 2016-05-31
ES2632461T3 (es) 2017-09-13
EP1296651B2 (en) 2019-07-17
EP1296651A1 (en) 2003-04-02
EP1913939B1 (en) 2017-05-31
EP2266549A3 (en) 2012-01-18
CN1438875A (zh) 2003-08-27
US20160243039A1 (en) 2016-08-25
US20100285142A1 (en) 2010-11-11
DE60131399T2 (de) 2008-04-17
IL153705A (en) 2011-02-28
US20030162835A1 (en) 2003-08-28
ES2292598T3 (es) 2008-03-16
JP2004501183A (ja) 2004-01-15
EP2266549B1 (en) 2019-08-07
DE60131399T3 (de) 2019-11-14
US20180055772A1 (en) 2018-03-01
CA2413692C (en) 2011-10-18
WO2002000197A1 (en) 2002-01-03
EP1913939A1 (en) 2008-04-23
CA2413692A1 (en) 2002-01-03
PT1296651E (pt) 2008-02-12
US7744855B2 (en) 2010-06-29
CN100551358C (zh) 2009-10-21

Similar Documents

Publication Publication Date Title
KR100949539B1 (ko) 약학 조성물용 입자의 제조 방법
EP1276472B1 (en) Formulations for use in inhaler devices
AU2001269261B2 (en) Method of making particles for use in a pharmaceutical composition
ZA200210225B (en) Method of making particles for use in a pharmaceutical composition.
AU2001269261A1 (en) Method of making particles for use in a pharmaceutical composition
NZ523246A (en) Composite excipient particles with a mass medium aerodynamic or a volume median diameter of less that 1 micron produced by milling
HK1152489B (en) Method of making particles for use in a pharmaceutical composition
HK1152489A (en) Method of making particles for use in a pharmaceutical composition
HK1152895A (en) Pharmaceutical formulations for dry powder inhalers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060524

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070530

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20071227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070530

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080331

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20071227

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080814

Appeal identifier: 2008101002833

Request date: 20080331

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080430

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080331

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070830

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20060524

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20080611

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080331

Effective date: 20080814

Free format text: TRIAL NUMBER: 2008101002833; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080331

Effective date: 20080814

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20080814

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20080331

Decision date: 20080814

Appeal identifier: 2008101002833

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090213

Patent event code: PE09021S01D

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20090910

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20090123

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20100305

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20100318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20100319

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20130311

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20130311

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20140310

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20140310

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20150306

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20150306

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20160308

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20160308

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20170314

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20170314

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20180307

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20180307

Start annual number: 9

End annual number: 9

PC1801 Expiration of term

Termination date: 20211227

Termination category: Expiration of duration